Shots: Takeda to receive $505M cash at closing, $70M in non-contingent cash to be paid within 4yrs. post-closing, $95M as milestones. Takeda will divest ~110 select OTC and prescription pharmaceutical assets sold in the EU The transaction is expected to be closed by the end of 2020. The divestiture will allow Takeda to prioritize and […]Read More
